Cellectis Inc.

Contributing Author

Recent Articles by Cellectis Inc.

May-06	Monthly information on share capital and company voting rights CLLS +5.05% GlobeNewswire
May-04	Cellectis to Report First Quarter Financial Results on May 11, 2026 CLLS -6.33% GlobeNewswire
Apr-27	Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting CLLS GlobeNewswire
Apr-13	Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T Platform CLLS +19.22% GlobeNewswire
Apr-07	Monthly information on share capital and company voting rights CLLS +5.65% CLLS GlobeNewswire
Mar-19	Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update CLLS GlobeNewswire
Mar-12	Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 CLLS -12.37% GlobeNewswire
Mar-04	Monthly information on share capital and company voting rights CLLS GlobeNewswire
Feb-04	Monthly information on share capital and company voting rights CLLS GlobeNewswire
Jan-08	Cellectis Announces 2026 Strategy and Catalysts CLLS GlobeNewswire
Jan-05	Monthly information on share capital and company voting rights CLLS -5.42% GlobeNewswire
Dec-15	Cellectis Announces Arbitral Decision in Dispute with Servier CLLS -15.24% CLLS GlobeNewswire
Dec-08	ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL CLLS GlobeNewswire
Dec-03	Monthly information on share capital and company voting rights CLLS GlobeNewswire
Nov-19	Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells CLLS +7.06% GlobeNewswire
Nov-07	Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update CLLS +11.29% CLLS GlobeNewswire
Nov-07	Monthly information on share capital and company voting rights CLLS +11.29% CLLS GlobeNewswire
Nov-03	Cellectis to Present a Development Update for eti-cel at ASH 2025 CLLS -5.22% GlobeNewswire
Oct-31	Cellectis to Report Third Quarter Financial Results on November 7, 2025 CLLS GlobeNewswire
Oct-16	Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL CLLS -11.95% CLLS +9.98% GlobeNewswire
Oct-16	Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers CLLS +9.98% GlobeNewswire
Oct-07	Monthly information on share capital and company voting rights CLLS +12.57% CLLS +8.22% GlobeNewswire
Oct-07	Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress CLLS +8.22% GlobeNewswire
Sep-03	Monthly information on share capital and company voting rights CLLS GlobeNewswire
Aug-07	Monthly information on share capital and company voting rights CLLS GlobeNewswire
Aug-04	Cellectis Reports Second Quarter 2025 Financial Results & Business Updates CLLS -16.23% CLLS GlobeNewswire
Jul-28	Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025 CLLS +13.10% GlobeNewswire
Jul-04	Monthly information on share capital and company voting rights CLLS GlobeNewswire
Jun-26	Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025 CLLS GlobeNewswire
Jun-05	Monthly information on share capital and company voting rights CLLS GlobeNewswire
May-21	Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025 CLLS GlobeNewswire
May-12	Cellectis Reports Financial Results for the First Quarter 2025 CLLS -6.62% CLLS GlobeNewswire
May-07	Monthly information on share capital and company voting rights CLLS GlobeNewswire
May-06	Cellectis to Report First Quarter Financial Results on May 12, 2025 CLLS GlobeNewswire

Cellectis Inc.

Recent Articles by Cellectis Inc.

Upgrade your Finviz experience